시장보고서
상품코드
1192962

재조합 백신 시장 : 적응증별(인유두종 바이러스, 수막염균, 기타), 최종 사용자별(소아, 성인), 유통 채널별(병원, 예방 접종 센터) - 세계 기회 분석 및 산업 예측(2021-2031년)

Recombinant Vaccines Market By Indication (Human Papillomavirus, Meningococcal, Others), By End User (Pediatric, Adults), By Distribution Channel (Hospitals, Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 258 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

재조합 백신의 세계 시장은 2021년에 80억 8,037만 달러, 2031년에는 246억 9,879만 달러에 이르렀으며, 2022년부터 2031년까지의 CAGR은 11.4%로 예측됩니다.

재조합 백신은 재조합 DNA 기술에 의해 제조된 백신을 말합니다. 이것은 면역 반응을 자극하는 항원 (세균 표면 단백질 등)을 코딩하는 DNA를 박테리아 또는 포유류 세포에 삽입하여 세포 내에서 항원을 발현시키고 세포에서 항원을 정제하는 것입니다. DNA, 단백질, 생백신의 형태로 발현된다. DNA의 것은 만드는 것이 싸고, 내열성이 있기 때문에 수송이나 보존을 위한 「콜드 체인」을 필요로 하지 않습니다. DNA 백신의 개발에 대해서는, 지금까지도 많은 연구가 행해져 왔다. 그러나 인간에게 사용할 수 있는 DNA 백신이 되는 데 성공한 것은 매우 적습니다. 생 재조합 백신은 표적 세포의 세포질에서 다양한 외래 항원, 이 경우 HIV-1과 유전자를 발현하도록 조작된 생 바이러스 또는 박테리아 벡터로 만들어집니다.

재조합 백신 시장의 성장은 재조합 백신의 R&D 활동 증가, 전염병 유행, 세계 백신 접종률의 증가로 이어지고 있다. 게다가 인수 공통 감염의 발생률 증가, 백신 개발을 위한 신흥 기술, 제품 승인 수의 증가도 시장 성장에 기여하고 있습니다. 예를 들어, 2021년 6월, 머크와 사노피는 미국에서 6종 혼합 소아용 백신의 승인을 받았으나, 새로운 백신의 도입 기간이 긴 것이 시장 성장을 저해할 것으로 예상됩니다. 반대로, 미개척 신흥국의 높은 성장 잠재력은 시장에 유리한 기회를 창출할 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 재조합 백신 시장 : 적응증별

  • 개요
    • 시장 규모 및 예측
  • 인유두종 바이러스
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 수막염균
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 재조합 백신 시장 : 최종 사용자별

  • 개요
    • 시장 규모·예측
  • 소아용
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 성인
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 재조합 백신 시장 : 유통 채널별

  • 개요
    • 시장 규모·예측
  • 병원
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별 분석
    • 병원용 재조합 백신 시장 : 유형별
      • 민간 시장 규모·예측 : 지역별
      • 공영 시장 규모 추이·예측 : 지역별
  • 백신 접종 센터
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제7장 재조합 백신 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 적응증별
    • 북미 시장 규모·예측 : 최종 사용자별
    • 북미 시장 규모·예측 : 유통 채널별
      • 북미의 병원용 재조합 백신 시장 : 유형별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽의 시장 규모·예측 : 적응증별
    • 유럽 시장 규모·예측 : 최종 사용자별
    • 유럽 시장 규모·예측 : 유통 채널별
      • 병원용 재조합 백신 유럽 시장 : 유형별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 적응증별
    • 아시아태평양의 시장 규모·예측 : 최종 사용자별
    • 아시아태평양의 시장 규모·예측 : 유통 채널별
      • 아시아태평양의 병원용 재조합 백신 시장 : 유형별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 적응증별
    • LAMEA의 시장 규모·예측 : 엔드유저별
    • LAMEA의 시장 규모·예측 : 유통채널별
      • LAMEA 병원용 재조합 백신 시장 : 유형별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 프로필

  • Pfizer Inc.
ksm 23.03.27

The global recombinant vaccines market was valued at $8,080.37 million in 2021, and is projected to reach $24,698.79 million by 2031, registering a CAGR of 11.4% from 2022 to 2031.

A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune response into bacterial or mammalian cells, expressing the antigen in these cells and then purifying it from them. It is expressed as DNA, proteins and live vaccines. The DNA version is cheaper to make and is thermostable, which does not require the "cold chain" for transportation and preservation. A large number of studies have been done on development of DNA vaccines. However, a few DNA vaccines have succeeded in becoming DNA vaccines for human use. The live recombinant vaccines are made of a live viral or bacterial vector that was engineered to express a variety of exogenous antigens in the cytoplasm of target cells, in this case HIV-1 or genes.

The growth of the recombinant vaccines market is driven by increase in research and development activities for recombinant vaccines, rise in the prevalence of infectious diseases and increase in rates of vaccinations globally. Moreover, increasing incidence of zoonotic diseases, emerging technologies for developing vaccines and rise in the number of product approvals also helps in the growth of the market. For instance, in June 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, prolong period for introduction of new vaccines is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The global recombinant vaccines market is segmented based on indication, end user, distribution channel and region. On the basis of indication, the market is bifurcated into human papillomavirus, meningococcal and others. On the basis of end user, the market is classified into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include, AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the recombinant vaccines market analysis from 2021 to 2031 to identify the prevailing recombinant vaccines market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the recombinant vaccines market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global recombinant vaccines market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

  • Human Papillomavirus
  • Meningococcal
  • Others

By End User

  • Pediatric
  • Adults

By Distribution Channel

  • Hospitals
    • Type
    • Private
    • Public
  • Vaccination Centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: RECOMBINANT VACCINES MARKET, BY INDICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Human Papillomavirus
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Meningococcal
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: RECOMBINANT VACCINES MARKET, BY END USER

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Pediatric
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Adults
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: RECOMBINANT VACCINES MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
    • 6.2.4 Hospitals Recombinant Vaccines Market by Type
      • 6.2.4.1 Private Market size and forecast, by region
      • 6.2.4.2 Public Market size and forecast, by region
  • 6.3 Vaccination Centers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: RECOMBINANT VACCINES MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Indication
    • 7.2.3 North America Market size and forecast, by End User
    • 7.2.4 North America Market size and forecast, by Distribution Channel
      • 7.2.4.1 North America Hospitals Recombinant Vaccines Market by Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Indication
      • 7.2.5.1.2 Market size and forecast, by End User
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Indication
      • 7.2.5.2.2 Market size and forecast, by End User
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Indication
      • 7.2.5.3.2 Market size and forecast, by End User
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Indication
    • 7.3.3 Europe Market size and forecast, by End User
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
      • 7.3.4.1 Europe Hospitals Recombinant Vaccines Market by Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Indication
      • 7.3.5.1.2 Market size and forecast, by End User
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Indication
      • 7.3.5.2.2 Market size and forecast, by End User
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Indication
      • 7.3.5.3.2 Market size and forecast, by End User
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Indication
      • 7.3.5.4.2 Market size and forecast, by End User
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Indication
      • 7.3.5.5.2 Market size and forecast, by End User
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Indication
      • 7.3.5.6.2 Market size and forecast, by End User
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Indication
    • 7.4.3 Asia-Pacific Market size and forecast, by End User
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
      • 7.4.4.1 Asia-Pacific Hospitals Recombinant Vaccines Market by Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Indication
      • 7.4.5.1.2 Market size and forecast, by End User
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Indication
      • 7.4.5.2.2 Market size and forecast, by End User
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Indication
      • 7.4.5.3.2 Market size and forecast, by End User
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Indication
      • 7.4.5.4.2 Market size and forecast, by End User
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Indication
      • 7.4.5.5.2 Market size and forecast, by End User
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Indication
      • 7.4.5.6.2 Market size and forecast, by End User
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Indication
    • 7.5.3 LAMEA Market size and forecast, by End User
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
      • 7.5.4.1 LAMEA Hospitals Recombinant Vaccines Market by Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Indication
      • 7.5.5.1.2 Market size and forecast, by End User
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Indication
      • 7.5.5.2.2 Market size and forecast, by End User
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Indication
      • 7.5.5.3.2 Market size and forecast, by End User
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Indication
      • 7.5.5.4.2 Market size and forecast, by End User
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Pfizer Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제